CSIRO says it welcomes public discussion about the ethics of Artificial Intelligence (AI) following the release of 'Artificial Intelligence: Australia’s Ethics Framework'.
The discussion paper, developed by CSIRO’s Data61, is designed to encourage a conversation on how Australia will develop and uses AI.
"It identifies key governance principles and measures that can be used to achieve the best possible results from AI, while keeping the well-being of Australians as the top priority," said CSIRO in a statement.
According to CSIRO chief executive, Dr Larry Marshall, as AI is increasingly used in homes, workplaces and communities, Australia must ensure it transforms industries and creates new jobs in the right way.
“As Australia’s national science agency, a focus on ethics, social licence to operate, and clear national benefit have always determined how we apply science and technology to solve Australia’s greatest challenges,” said Dr Marshall.
“The draft framework contextualises these age-old ethical considerations in the light of new technology, so everyone can have a say in inventing the future we need so our children can keep pace with emerging technologies like AI.”
Adrian Turner, CEO at CSIRO’s Data61, said AI is already here and developing quickly.
“AI represents a powerful general purpose technology that will help Australia solve some of our biggest problems relating to energy, health, ageing, safety, security, climate and the environment.”
“However, we will only realise this potential if we address underlying science and technology challenges in AI itself as well as its implications for people.
"Because of the deep influence AI will have on us all, we need to ensure that these systems work for us and deliver benefits individually and collectively.
"The AI ethics framework identifies principles and tools for achieving this in practice,” said Mr Turner.
New Stories
-
AusMedtech 2026 unveiled as the industry gathers in Perth for landmark year
February 19, 2026 - - AusBiotech -
Medical Developments International builds momentum as Penthrox growth offsets softer respiratory demand
February 19, 2026 - - Latest News -
CSL in new strategic deal to advance promising anti-inflammatory therapy
February 18, 2026 - - Latest News -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Percheron targets next wave of immunotherapy with novel VISTA checkpoint candidate
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Latest News -
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Latest News